Contineum Therapeutics, Inc.(CTNM) - 2025 Q1 - Quarterly Results

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed ...